{"transactions":[{"id":4616752,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-14T20:00:08.000Z","date":"2026-09-10","kind":"sale","planned":false,"acquired":false,"shares":1042,"price":33.2302,"value":34625.8684,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.84 to $33.45. Full information regarding the number of shares sold at each separate price can be\nfurnished to the SEC staff upon request."}],"balance_after":233625,"source":{"system":"sec-edgar","filing":"0001193125-26-390509","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526390509/ownership.xml","form_type":"4"}},{"id":4616751,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-09-14T20:00:08.000Z","date":"2026-09-10","kind":"sale","planned":false,"acquired":false,"shares":9768,"price":32.2681,"value":315194.8008,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.805  to $32.71. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":234667,"source":{"system":"sec-edgar","filing":"0001193125-26-390509","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526390509/ownership.xml","form_type":"4"}},{"id":679861,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-21T01:00:09.000Z","date":"2026-08-18","kind":"grant","planned":false,"acquired":true,"shares":22807,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported shares are represented by performance share units, or PSUs, and were awarded upon the achievement of certain performance metrics. Shares subject to the PSU vested on August 18, 2026."}],"balance_after":244435,"source":{"system":"sec-edgar","filing":"0001193125-26-359679","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526359679/ownership.xml","form_type":"4"}},{"id":853496,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2026-03-09T20:00:07.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":143985,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the option shall vest and become exercisable on March 1, 2027, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date."}],"balance_after":143985,"derivative":{"exercise_price":14.1,"expiration_date":"2036-03-05","underlying":"Common Stock","underlying_shares":143985},"source":{"system":"sec-edgar","filing":"0001193125-26-098438","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526098438/ownership.xml","form_type":"4"}},{"id":853495,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-09T20:00:07.000Z","date":"2026-03-05","kind":"grant","planned":false,"acquired":true,"shares":95990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit (\"RSU\") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2027, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":261628,"source":{"system":"sec-edgar","filing":"0001193125-26-098438","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526098438/ownership.xml","form_type":"4"}},{"id":861573,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-03-04T21:00:04.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":7909,"price":14.5216,"value":114851.3344,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.450 to $15.385. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":165638,"source":{"system":"sec-edgar","filing":"0001193125-26-091438","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526091438/ownership.xml","form_type":"4"}},{"id":919388,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-02-04T21:05:19.000Z","date":"2026-02-02","kind":"sale","planned":false,"acquired":false,"shares":3557,"price":14.6463,"value":52096.8891,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock\nunits. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock\nunits. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.460 to $14.790.\nFull information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":173547,"source":{"system":"sec-edgar","filing":"0001193125-26-037553","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526037553/ownership.xml","form_type":"4"}},{"id":943203,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-01-08T21:05:17.000Z","date":"2026-01-06","kind":"sale","planned":false,"acquired":false,"shares":3326,"price":11.1106,"value":36953.8556,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $10.99 to $11.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":177104,"source":{"system":"sec-edgar","filing":"0001193125-26-007669","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526007669/ownership.xml","form_type":"4"}},{"id":1027181,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-10-02T20:15:12.000Z","date":"2025-09-30","kind":"sale","planned":false,"acquired":false,"shares":10558,"price":14.6477,"value":154650.4166,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $14.35 to $15.075. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":280430,"source":{"system":"sec-edgar","filing":"0001193125-25-228341","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000119312525228341/ownership.xml","form_type":"4"}},{"id":1078297,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-31T15:28:26.000Z","date":"2025-07-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":21500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a \"Company Option\") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a \"Company Option\") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":6.77,"expiration_date":"2035-06-10","underlying":"Common Stock","underlying_shares":21500},"source":{"system":"sec-edgar","filing":"0000950170-25-100653","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000095017025100653/ownership.xml","form_type":"4"}},{"id":1078296,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-07-31T15:28:26.000Z","date":"2025-07-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19154,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a \"Company Option\") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a \"Company Option\") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":6.14,"expiration_date":"2035-01-03","underlying":"Common Stock","underlying_shares":19154},"source":{"system":"sec-edgar","filing":"0000950170-25-100653","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000095017025100653/ownership.xml","form_type":"4"}},{"id":1078295,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-07-31T15:28:26.000Z","date":"2025-07-31","kind":"other","planned":false,"acquired":false,"shares":2845,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the \"Issuer\"), Supernus Pharmaceuticals, Inc. (\"Parent\"), and Saphire, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the \"Closing Amount\"), plus (ii) one contingent value right (\"CVR\") per Share, each without interest and subject to the withholding of applicable taxes."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the \"Issuer\"), Supernus Pharmaceuticals, Inc. (\"Parent\"), and Saphire, Inc., a wholly owned subsidiary of Parent (\"Purchaser\"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the \"Closing Amount\"), plus (ii) one contingent value right (\"CVR\") per Share, each without interest and subject to the withholding of applicable taxes."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-25-100653","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000095017025100653/ownership.xml","form_type":"4"}},{"id":1111303,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-13T20:13:57.000Z","date":"2025-06-11","kind":"grant","planned":false,"acquired":true,"shares":21500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan in accordance with Sage's Non-Employee Director Compensation Program. The option will vest in full upon the earlier to occur of June 11, 2026 or the day immediately prior to the 2026 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date."}],"balance_after":21500,"derivative":{"exercise_price":6.77,"expiration_date":"2035-06-11","underlying":"Common Stock","underlying_shares":21500},"source":{"system":"sec-edgar","filing":"0001562180-25-004791","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000156218025004791/primarydocument.xml","form_type":"4"}},{"id":1183409,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-04-02T21:22:59.000Z","date":"2025-03-31","kind":"sale","planned":false,"acquired":false,"shares":10896,"price":3.4697,"value":37805.8512,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $3.44 to $3.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":290988,"source":{"system":"sec-edgar","filing":"0000950170-25-049581","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025049581/ownership.xml","form_type":"4"}},{"id":1215020,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-11T00:28:19.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":102630,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option shall vest and become exercisable on March 1, 2026, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date."}],"balance_after":102630,"derivative":{"exercise_price":3.61,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":102630},"source":{"system":"sec-edgar","filing":"0000950170-25-036707","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025036707/ownership.xml","form_type":"4"}},{"id":1215019,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2025-03-11T00:28:19.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":68420,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit (\"RSU\") award. The RSUs shall vest in 4 equal annual installments, with the first installment vesting on March 1, 2026, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":301884,"source":{"system":"sec-edgar","filing":"0000950170-25-036707","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017025036707/ownership.xml","form_type":"4"}},{"id":1310079,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2025-01-06T21:02:45.000Z","date":"2025-01-03","kind":"grant","planned":false,"acquired":true,"shares":19154,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person elected to receive this stock option award in lieu of payment of all cash retainers that would otherwise be paid for the reporting person's service during 2025 on the issuer's board or its committees, as permitted under the issuer's non-employee director compensation program. The stock option is granted under and subject to the terms of the Sage Therapeutics, Inc. 2024 Equity Incentive Plan. The option will vest in full on December 31, 2025, subject to the reporting person's continued service through such date."}],"balance_after":19154,"derivative":{"exercise_price":6.14,"expiration_date":"2035-01-03","underlying":"Common Stock","underlying_shares":19154},"source":{"system":"sec-edgar","filing":"0001562180-25-000163","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000156218025000163/primarydocument.xml","form_type":"4"}},{"id":1406622,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-16T21:30:37.000Z","date":"2024-09-12","kind":"purchase","planned":false,"acquired":true,"shares":40000,"price":2.5342,"value":101368.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $2.4849 to $2.63. Full information regarding the number of shares purchased at each separate price can be furnished to the SEC staff upon request."}],"balance_after":233464,"source":{"system":"sec-edgar","filing":"0000950170-24-106910","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024106910/ownership.xml","form_type":"4"}},{"id":1413924,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-09-05T23:55:42.000Z","date":"2023-08-23","kind":"exercise","planned":false,"acquired":false,"shares":18165,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"113,024 shares underlying this option vested on January 25, 2022, with the remaining shares vesting in monthly installments of 9,416 shares thereafter."}],"balance_after":363835,"derivative":{"exercise_price":6.88,"expiration_date":"2031-01-25","underlying":"Common Stock","underlying_shares":18165},"source":{"system":"sec-edgar","filing":"0000950170-24-104191","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024104191/ownership.xml","form_type":"4/A","original_submission_date":"2023-08-24"}},{"id":1413923,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-09-05T23:55:42.000Z","date":"2023-08-23","kind":"exercise","planned":false,"acquired":true,"shares":18165,"price":6.88,"value":124975.2,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On August 24, 2023, a Form 4 was filed on behalf of the Reporting Person which inadvertently overstated the number of securities reported in Column 5 of Table I by 32,500 shares due to an administrative error. This Form 4 amendment is being filed to correct the aggregate number of shares beneficially owned by the Reporting Person as of the original transaction date, as well as the corresponding amounts that were carried forward on Form 4 reports subsequently filed on behalf of the Reporting Person."}],"balance_after":73841,"source":{"system":"sec-edgar","filing":"0000950170-24-104191","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024104191/ownership.xml","form_type":"4/A","original_submission_date":"2023-08-24"}},{"id":1483213,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-06-11T20:58:01.000Z","date":"2024-06-10","kind":"grant","planned":false,"acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2024 Equity Incentive Plan in accordance with Sage's Non-Employee Director Compensation Program. The option will vest in full upon the earlier to occur of June 10, 2025 or the day immediately prior to the 2025 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date."}],"balance_after":12500,"derivative":{"exercise_price":10.9,"expiration_date":"2034-06-09","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001562180-24-004950","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000156218024004950/primarydocument.xml","form_type":"4"}},{"id":1539205,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-04-19T00:23:43.000Z","date":"2024-04-16","kind":"grant","planned":false,"acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option shall vest and become exercisable on April 16, 2025, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through each such vesting date."}],"balance_after":120000,"derivative":{"exercise_price":2.01,"expiration_date":"2034-04-15","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0000950170-24-045698","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024045698/ownership.xml","form_type":"4"}},{"id":1539204,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-04-19T00:23:43.000Z","date":"2024-04-16","kind":"grant","planned":false,"acquired":true,"shares":91180,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit (\"RSU\") award. The RSUs shall vest as follows: 33% on September 30, 2024, 33% on March 31, 2025 and 34% on September 30, 2025, subject to the Reporting Person's continued service to the Issuer through each such vesting date."}],"balance_after":225964,"source":{"system":"sec-edgar","filing":"0000950170-24-045698","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024045698/ownership.xml","form_type":"4"}},{"id":1589113,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-03-07T21:05:11.000Z","date":"2024-03-05","kind":"sale","planned":false,"acquired":false,"shares":1792,"price":18.7279,"value":33560.3968,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.62 to $18.82. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":134784,"source":{"system":"sec-edgar","filing":"0000950170-24-027918","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024027918/ownership.xml","form_type":"4"}},{"id":1612290,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2024-02-28T23:44:10.000Z","date":"2024-02-26","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":60000,"derivative":{"exercise_price":17.56,"expiration_date":"2034-02-25","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-24-022434","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024022434/ownership.xml","form_type":"4"}},{"id":1612289,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-02-28T23:44:10.000Z","date":"2024-02-26","kind":"grant","planned":false,"acquired":true,"shares":40000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit (\"RSU\") award. The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date."}],"balance_after":152035,"source":{"system":"sec-edgar","filing":"0000950170-24-022434","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024022434/ownership.xml","form_type":"4"}},{"id":1680728,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2024-01-11T22:11:49.000Z","date":"2024-01-09","kind":"sale","planned":false,"acquired":false,"shares":2716,"price":16.3281,"value":44347.1196,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not at the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.18 to $16.70. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":112035,"source":{"system":"sec-edgar","filing":"0000950170-24-003984","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017024003984/ownership.xml","form_type":"4"}},{"id":1687345,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Options (Right to buy)","published_at":"2024-01-04T21:07:47.000Z","date":"2024-01-03","kind":"grant","planned":false,"acquired":true,"shares":4925,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The reporting person elected to receive this stock option award in lieu of payment of all cash retainers that would otherwise be paid for the reporting person's service during 2024 on the issuer's board or its committees, as permitted under the issuer's amended and restated non-employee director compensation policy. The stock option is granted under and subject to the terms of the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan. The option will vest in full on December 31, 2024, subject to the reporting person's continued service through such date."}],"balance_after":4925,"derivative":{"exercise_price":21.67,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":4925},"source":{"system":"sec-edgar","filing":"0001562180-24-000226","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000156218024000226/primarydocument.xml","form_type":"4"}},{"id":1751344,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-11-02T19:33:04.000Z","date":"2023-10-31","kind":"gift","planned":false,"acquired":true,"shares":11072,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On October 31, 2023, the James M. Frates Grantor Retained Annuity Trust 2021, for which the Reporting Person served as trustee and sole annuitant, liquidated and returned 8,410 shares to the Reporting Person as an annuity payment, transferring the remaining 11,072 shares to the FRATES FAMILY 2013 IRREV TRUST for no consideration."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Shares held by the FRATES FAMILY 2013 IRREV TRUST, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose."}],"balance_after":11072,"source":{"system":"sec-edgar","filing":"0000950170-23-058113","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017023058113/ownership.xml","form_type":"4"}},{"id":1797706,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-08-24T20:15:54.000Z","date":"2023-08-23","kind":"exercise","planned":false,"acquired":false,"shares":18165,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"113,024 shares underlying this option vested on January 25, 2022, with the remaining shares vesting in monthly installments of 9,416 shares thereafter."}],"balance_after":363835,"derivative":{"exercise_price":6.88,"expiration_date":"2031-01-25","underlying":"Common Stock","underlying_shares":18165},"source":{"system":"sec-edgar","filing":"0000950170-23-044381","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017023044381/ownership.xml","form_type":"4"}},{"id":1797705,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-08-24T20:15:54.000Z","date":"2023-08-23","kind":"exercise","planned":false,"acquired":true,"shares":18165,"price":6.88,"value":124975.2,"ownership":{"direct":true},"balance_after":106341,"source":{"system":"sec-edgar","filing":"0000950170-23-044381","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000095017023044381/ownership.xml","form_type":"4"}},{"id":1851792,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-06-16T20:06:29.000Z","date":"2023-06-15","kind":"grant","planned":false,"acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 15, 2024 or the day immediately prior to the 2024 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date."}],"balance_after":10000,"derivative":{"exercise_price":56.1,"expiration_date":"2033-06-15","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-23-005265","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000156218023005265/primarydocument.xml","form_type":"4"}},{"id":1886863,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-05-19T00:54:37.000Z","date":"2023-05-16","kind":"exercise","planned":true,"acquired":false,"shares":32500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"113,024 shares underlying this option vested on January 25, 2022, with the remaining shares vesting in monthly installments of 9,416 shares thereafter."}],"balance_after":382000,"derivative":{"exercise_price":6.88,"expiration_date":"2031-01-25","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0000899243-23-013289","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323013289/doc4.xml","form_type":"4"}},{"id":1886862,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-19T00:54:37.000Z","date":"2023-05-16","kind":"sale","planned":true,"acquired":false,"shares":500,"price":27.6,"value":13800.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.59 to $27.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":55676,"source":{"system":"sec-edgar","filing":"0000899243-23-013289","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323013289/doc4.xml","form_type":"4"}},{"id":1886861,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-19T00:54:37.000Z","date":"2023-05-16","kind":"sale","planned":true,"acquired":false,"shares":32000,"price":26.9266,"value":861651.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.36 to $27.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":56176,"source":{"system":"sec-edgar","filing":"0000899243-23-013289","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323013289/doc4.xml","form_type":"4"}},{"id":1886860,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-05-19T00:54:37.000Z","date":"2023-05-16","kind":"exercise","planned":true,"acquired":true,"shares":32500,"price":6.88,"value":223600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022."}],"balance_after":88176,"source":{"system":"sec-edgar","filing":"0000899243-23-013289","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323013289/doc4.xml","form_type":"4"}},{"id":1913326,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series C-1 Preferred Stock","published_at":"2023-04-26T23:34:34.000Z","date":"2022-01-06","kind":"exercise","planned":false,"acquired":false,"shares":19482,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Series C-1 Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Series C-1 Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This amendment on Form 4/A to the Form 4 originally filed on January 10, 2022 (the \"Original Form 4\") is being filed solely to report the conversion of 19,482 shares of Series C-1 Preferred Stock into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering, which was inadvertently omitted from the Original Form 4."},{"field":"shares","element":"transactionShares","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Series C-1 Preferred Stock had no expiration date."},{"field":"shares","element":"transactionShares","label":"F2","text":"This amendment on Form 4/A to the Form 4 originally filed on January 10, 2022 (the \"Original Form 4\") is being filed solely to report the conversion of 19,482 shares of Series C-1 Preferred Stock into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering, which was inadvertently omitted from the Original Form 4."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Series C-1 Preferred Stock had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Series C-1 Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Series C-1 Preferred Stock had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"This amendment on Form 4/A to the Form 4 originally filed on January 10, 2022 (the \"Original Form 4\") is being filed solely to report the conversion of 19,482 shares of Series C-1 Preferred Stock into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering, which was inadvertently omitted from the Original Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the James M. Frates Grantor Retained Annuity Trust 2021, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":19482},"source":{"system":"sec-edgar","filing":"0000899243-23-011781","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323011781/doc4a.xml","form_type":"4/A","original_submission_date":"2022-01-10"}},{"id":1913325,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-04-26T23:34:34.000Z","date":"2022-01-06","kind":"exercise","planned":false,"acquired":true,"shares":19482,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"By Trust"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Series C-1 Preferred Stock had no expiration date."},{"field":"kind","element":"transactionCoding","label":"F2","text":"This amendment on Form 4/A to the Form 4 originally filed on January 10, 2022 (the \"Original Form 4\") is being filed solely to report the conversion of 19,482 shares of Series C-1 Preferred Stock into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering, which was inadvertently omitted from the Original Form 4."},{"field":"shares","element":"transactionShares","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Series C-1 Preferred Stock had no expiration date."},{"field":"shares","element":"transactionShares","label":"F2","text":"This amendment on Form 4/A to the Form 4 originally filed on January 10, 2022 (the \"Original Form 4\") is being filed solely to report the conversion of 19,482 shares of Series C-1 Preferred Stock into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering, which was inadvertently omitted from the Original Form 4."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Upon the closing of the Issuer's initial public offering, all shares of Series C-1 Preferred Stock automatically converted into the number of shares of the Issuer's Common Stock shown in column 4 of Table I without payment or further consideration. The Series C-1 Preferred Stock had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This amendment on Form 4/A to the Form 4 originally filed on January 10, 2022 (the \"Original Form 4\") is being filed solely to report the conversion of 19,482 shares of Series C-1 Preferred Stock into shares of the Issuer's Common Stock upon the closing of the Issuer's initial public offering, which was inadvertently omitted from the Original Form 4."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"Shares held by the James M. Frates Grantor Retained Annuity Trust 2021, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of such shares for purposes of Section 16 except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that such shares are beneficially owned by him for Section 16 or any other purpose."}],"balance_after":19482,"source":{"system":"sec-edgar","filing":"0000899243-23-011781","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323011781/doc4a.xml","form_type":"4/A","original_submission_date":"2022-01-10"}},{"id":1939112,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-24T22:48:19.000Z","date":"2023-03-16","kind":"exercise","planned":false,"acquired":false,"shares":32500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 16, 2023, the Reporting Person filed a Form 4 (the \"Original Form 4\") which inadvertently omitted the exercise of 32,500 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer (\"Common Stock\") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4."},{"field":"kind","element":"transactionCoding","label":"F2","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"113,024 shares underlying this option vested on January 25, 2022, with the remaining shares vesting in monthly installments of 9,416 shares thereafter."}],"balance_after":414500,"derivative":{"exercise_price":6.88,"expiration_date":"2031-01-25","underlying":"Common Stock","underlying_shares":32500},"source":{"system":"sec-edgar","filing":"0000899243-23-009602","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323009602/doc4a.xml","form_type":"4/A","original_submission_date":"2023-03-20"}},{"id":1939111,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-24T22:48:19.000Z","date":"2023-03-16","kind":"grant","planned":false,"acquired":true,"shares":97500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":97500,"derivative":{"exercise_price":32.08,"expiration_date":"2033-03-16","underlying":"Common Stock","underlying_shares":97500},"source":{"system":"sec-edgar","filing":"0000899243-23-009602","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323009602/doc4a.xml","form_type":"4/A","original_submission_date":"2023-03-20"}},{"id":1939110,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-24T22:48:19.000Z","date":"2023-03-16","kind":"grant","planned":false,"acquired":true,"shares":21667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F5","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a \"RSU\"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On March 16, 2023, the Reporting Person filed a Form 4 (the \"Original Form 4\") which inadvertently omitted the exercise of 32,500 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer (\"Common Stock\") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4."}],"balance_after":55676,"source":{"system":"sec-edgar","filing":"0000899243-23-009602","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323009602/doc4a.xml","form_type":"4/A","original_submission_date":"2023-03-20"}},{"id":1939109,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-24T22:48:19.000Z","date":"2023-03-16","kind":"sale","planned":false,"acquired":false,"shares":1704,"price":32.4649,"value":55320.1896,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.33 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On March 16, 2023, the Reporting Person filed a Form 4 (the \"Original Form 4\") which inadvertently omitted the exercise of 32,500 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer (\"Common Stock\") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4."}],"balance_after":34009,"source":{"system":"sec-edgar","filing":"0000899243-23-009602","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323009602/doc4a.xml","form_type":"4/A","original_submission_date":"2023-03-20"}},{"id":1939108,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-24T22:48:19.000Z","date":"2023-03-16","kind":"sale","planned":false,"acquired":false,"shares":30796,"price":31.8593,"value":981139.0028,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.33 to $32.30. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On March 16, 2023, the Reporting Person filed a Form 4 (the \"Original Form 4\") which inadvertently omitted the exercise of 32,500 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer (\"Common Stock\") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4."}],"balance_after":35713,"source":{"system":"sec-edgar","filing":"0000899243-23-009602","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323009602/doc4a.xml","form_type":"4/A","original_submission_date":"2023-03-20"}},{"id":1939107,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-24T22:48:19.000Z","date":"2023-03-16","kind":"exercise","planned":false,"acquired":true,"shares":32500,"price":6.88,"value":223600.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 16, 2023, the Reporting Person filed a Form 4 (the \"Original Form 4\") which inadvertently omitted the exercise of 32,500 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer (\"Common Stock\") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4."},{"field":"kind","element":"transactionCoding","label":"F2","text":"These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On March 16, 2023, the Reporting Person filed a Form 4 (the \"Original Form 4\") which inadvertently omitted the exercise of 32,500 options by the Reporting Person. The Original Form 4 reported the sale of shares of Common Stock of the Issuer (\"Common Stock\") underlying those options, pursuant to a Rule 10b5-1 trading plan. This Form 4 amendment is being filed for the purpose of amending and restating the Original Form 4 solely to report the exercise of the stock options and the resulting increase in beneficial ownership of Common Stock. The Reporting Person has not sold any additional shares of Common Stock beyond those sales reported in the Original Form 4."}],"balance_after":66509,"source":{"system":"sec-edgar","filing":"0000899243-23-009602","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323009602/doc4a.xml","form_type":"4/A","original_submission_date":"2023-03-20"}},{"id":1944493,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2023-03-21T00:18:57.000Z","date":"2023-03-16","kind":"grant","planned":false,"acquired":true,"shares":97500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"1/4 of the shares subject to the option shall vest and become exercisable on the first day of the month of the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":97500,"derivative":{"exercise_price":32.08,"expiration_date":"2033-03-16","underlying":"Common Stock","underlying_shares":97500},"source":{"system":"sec-edgar","filing":"0000899243-23-009168","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323009168/doc4.xml","form_type":"4"}},{"id":1944492,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-21T00:18:57.000Z","date":"2023-03-16","kind":"grant","planned":false,"acquired":true,"shares":21667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F4","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a \"RSU\"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first day of the month of the one year anniversary of the date of grant, subject to the Reporting Person's continued service to the Issuer through such vesting date."}],"balance_after":23176,"source":{"system":"sec-edgar","filing":"0000899243-23-009168","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323009168/doc4.xml","form_type":"4"}},{"id":1944491,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-21T00:18:57.000Z","date":"2023-03-16","kind":"sale","planned":false,"acquired":false,"shares":1704,"price":32.4649,"value":55320.1896,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.33 to $32.93. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":1509,"source":{"system":"sec-edgar","filing":"0000899243-23-009168","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323009168/doc4.xml","form_type":"4"}},{"id":1944490,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-03-21T00:18:57.000Z","date":"2023-03-16","kind":"sale","planned":false,"acquired":false,"shares":30796,"price":31.8593,"value":981139.0028,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These sales were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2022."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.33 to $32.30. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":3213,"source":{"system":"sec-edgar","filing":"0000899243-23-009168","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323009168/doc4.xml","form_type":"4"}},{"id":2057508,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-01-11T00:20:38.000Z","date":"2023-01-06","kind":"sale","acquired":true,"shares":822,"price":36.7888,"value":30240.3936,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $36.59 to $37.01. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":34009,"source":{"system":"sec-edgar","filing":"0000899243-23-001523","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323001523/doc4.xml","form_type":"4"}},{"id":2057507,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-01-11T00:20:38.000Z","date":"2023-01-06","kind":"sale","acquired":true,"shares":1836,"price":36.0789,"value":66240.8604,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and intended to qualify under Rule 10b5-1."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $35.59 to $36.58. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request."}],"balance_after":34831,"source":{"system":"sec-edgar","filing":"0000899243-23-001523","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323001523/doc4.xml","form_type":"4"}},{"id":2067638,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-05T02:33:55.000Z","date":"2022-12-30","kind":"exercise","acquired":false,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"113,024 shares underlying this option vested on January 25, 2022, with the remaining shares vesting in monthly installments of 9,416 shares thereafter."}],"balance_after":447000,"derivative":{"exercise_price":6.88,"expiration_date":"2031-01-25","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000899243-23-000755","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323000755/doc4.xml","form_type":"4"}},{"id":2067637,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2023-01-05T02:33:55.000Z","date":"2022-12-30","kind":"exercise","acquired":true,"shares":5000,"price":6.88,"value":34400.0,"ownership":{"direct":true},"balance_after":36667,"source":{"system":"sec-edgar","filing":"0000899243-23-000755","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924323000755/doc4.xml","form_type":"4"}},{"id":2227305,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-17T20:36:17.000Z","date":"2022-06-16","kind":"grant","acquired":true,"shares":9947,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 16, 2023 or the day immediately prior to the 2023 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date."}],"balance_after":9947,"derivative":{"exercise_price":31.36,"expiration_date":"2032-06-16","underlying":"Common Stock","underlying_shares":9947},"source":{"system":"sec-edgar","filing":"0001562180-22-005207","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000156218022005207/primarydocument.xml","form_type":"4"}},{"id":2316629,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-28T20:30:25.000Z","date":"2022-02-11","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/4 of the shares subject to the option shall vest and become exercisable on the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":25000,"derivative":{"exercise_price":19.625,"expiration_date":"2032-02-11","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-22-012474","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924322012474/doc4.xml","form_type":"4"}},{"id":2438910,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2022-01-11T01:28:39.000Z","date":"2022-01-06","kind":"grant","acquired":true,"shares":142500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4 of the shares subject to the option shall vest and become exercisable on the one year anniversary of the date of grant, and the remaining shares shall vest monthly over the remaining 36 months, subject to the Reporting Person's continuous service to the Issuer through such vesting date."}],"balance_after":142500,"derivative":{"exercise_price":19,"expiration_date":"2032-01-06","underlying":"Common Stock","underlying_shares":142500},"source":{"system":"sec-edgar","filing":"0000899243-22-001512","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924322001512/doc4.xml","form_type":"4"}},{"id":2438909,"issuer":{"id":259,"kind":"organization","name":"Amylyx Pharmaceuticals, Inc.","symbol":"AMLX"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2022-01-11T01:28:39.000Z","date":"2022-01-06","kind":"grant","acquired":true,"shares":31667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The reported transaction involves the Reporting Person's receipt of a restricted stock unit award (a \"RSU\"). The RSU shall vest in 4 equal annual installments, with the first installment vesting on the first anniversary of the date of the grant, subject to the Reporting Person's continued service to the Issuer through such vesting date."}],"balance_after":31667,"source":{"system":"sec-edgar","filing":"0000899243-22-001512","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1658551/000089924322001512/doc4.xml","form_type":"4"}},{"id":2663251,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-06-17T20:04:47.000Z","date":"2021-06-16","kind":"purchase","acquired":true,"shares":1810,"price":55.102,"value":99734.62,"ownership":{"direct":false,"nature":"See Footnote 2"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $55.08 USD to $55.11 USD. The price reported above reflects the weighted average sale price. The issuer hereby undertakes to provide, upon request, to the SEC staff or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents 905 shares held directly by the John A. Frates 2013 Irrevocable Trust, dated December 19, 2013, and 905 shares held directly by the Peter E. Frates 2013 Irrevocable Trust, dated December 19, 2013. The reporting person disclaims Section 16 beneficial ownership of the shares held in each of these trusts, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed an admission that the reporting person is the beneficial owner of these shares for purposes of Section 16 or for any other purpose."}],"balance_after":1810,"source":{"system":"sec-edgar","filing":"0001562180-21-004347","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000156218021004347/primarydocument.xml","form_type":"4"}},{"id":2671629,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-11T20:11:58.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 10, 2022 or the day immediately prior to the 2022 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date."}],"balance_after":10000,"derivative":{"exercise_price":76.09,"expiration_date":"2031-06-10","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-21-004210","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000156218021004210/primarydocument.xml","form_type":"4"}},{"id":3113160,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-06-11T20:18:13.000Z","date":"2020-06-09","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc. 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 9, 2021 or the day immediately prior to the 2021 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date."}],"balance_after":10000,"derivative":{"exercise_price":36.47,"expiration_date":"2030-06-09","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-20-004427","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000156218020004427/primarydocument.xml","form_type":"4"}},{"id":3148656,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-05-14T20:58:09.000Z","date":"2020-05-14","kind":"exercise","acquired":false,"shares":21983,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options are fully vested in accordance with their terms."}],"balance_after":0,"derivative":{"exercise_price":11.74,"expiration_date":"2020-05-17","underlying":"Ordinary Shares","underlying_shares":21983},"source":{"system":"sec-edgar","filing":"0001127602-20-016615","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760220016615/form4.xml","form_type":"4"}},{"id":3148655,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Ordinary Shares","published_at":"2020-05-14T20:58:09.000Z","date":"2020-05-14","kind":"exercise","acquired":true,"shares":21983,"price":11.74,"value":258080.42,"ownership":{"direct":true},"balance_after":91828,"source":{"system":"sec-edgar","filing":"0001127602-20-016615","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760220016615/form4.xml","form_type":"4"}},{"id":3231592,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Restricted Stock Unit Award","published_at":"2020-03-03T21:27:02.000Z","date":"2020-03-01","kind":"exercise","acquired":false,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/1/2017."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/1/2017."}],"balance_after":0,"derivative":{"exercise_price":0,"exercise_date":"2017-03-01","underlying":"Ordinary Shares","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001127602-20-008995","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760220008995/form4.xml","form_type":"4"}},{"id":3231591,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Ordinary Shares","published_at":"2020-03-03T21:27:02.000Z","date":"2020-03-01","kind":"tax_withholding","acquired":false,"shares":1323,"price":20.84,"value":27571.32,"ownership":{"direct":true},"balance_after":69845,"source":{"system":"sec-edgar","filing":"0001127602-20-008995","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760220008995/form4.xml","form_type":"4"}},{"id":3231590,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Ordinary Shares","published_at":"2020-03-03T21:27:02.000Z","date":"2020-03-01","kind":"exercise","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":71168,"source":{"system":"sec-edgar","filing":"0001127602-20-008995","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760220008995/form4.xml","form_type":"4"}},{"id":3252572,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Restricted Stock Unit Award","published_at":"2020-02-24T21:11:14.000Z","date":"2020-02-21","kind":"exercise","acquired":false,"shares":5825,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/21/2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/21/2020."}],"balance_after":17475,"derivative":{"exercise_price":0,"exercise_date":"2020-02-21","underlying":"Ordinary Shares","underlying_shares":5825},"source":{"system":"sec-edgar","filing":"0001127602-20-007180","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760220007180/form4.xml","form_type":"4"}},{"id":3252571,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Restricted Stock Unit Award","published_at":"2020-02-24T21:11:14.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":24474,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/20/2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/20/2021."}],"balance_after":24474,"derivative":{"exercise_price":0,"exercise_date":"2021-02-20","underlying":"Ordinary Shares","underlying_shares":24474},"source":{"system":"sec-edgar","filing":"0001127602-20-007180","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760220007180/form4.xml","form_type":"4"}},{"id":3252570,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2020-02-24T21:11:14.000Z","date":"2020-02-20","kind":"grant","acquired":true,"shares":102337,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares subject to the stock option award vest in four equal annual installments commencing on 2/20/2021."}],"balance_after":102337,"derivative":{"exercise_price":20.43,"exercise_date":"2021-02-20","expiration_date":"2030-02-20","underlying":"Ordinary Shares","underlying_shares":102337},"source":{"system":"sec-edgar","filing":"0001127602-20-007180","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760220007180/form4.xml","form_type":"4"}},{"id":3252569,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Ordinary Shares","published_at":"2020-02-24T21:11:14.000Z","date":"2020-02-21","kind":"tax_withholding","acquired":false,"shares":1712,"price":20.24,"value":34650.88,"ownership":{"direct":true},"balance_after":66668,"source":{"system":"sec-edgar","filing":"0001127602-20-007180","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760220007180/form4.xml","form_type":"4"}},{"id":3252568,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Ordinary Shares","published_at":"2020-02-24T21:11:14.000Z","date":"2020-02-21","kind":"exercise","acquired":true,"shares":5825,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":68380,"source":{"system":"sec-edgar","filing":"0001127602-20-007180","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760220007180/form4.xml","form_type":"4"}},{"id":3266430,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Restricted Stock Unit Award","published_at":"2020-02-18T21:07:52.000Z","date":"2020-02-17","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/17/18."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/17/18."}],"balance_after":3000,"derivative":{"exercise_price":0,"exercise_date":"2018-02-17","underlying":"Ordinary Shares","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001127602-20-006015","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760220006015/form4.xml","form_type":"4"}},{"id":3266429,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Restricted Stock Unit Award","published_at":"2020-02-18T21:07:52.000Z","date":"2020-02-16","kind":"exercise","acquired":false,"shares":3375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/16/19."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/16/19."}],"balance_after":6750,"derivative":{"exercise_price":0,"exercise_date":"2019-02-16","underlying":"Ordinary Shares","underlying_shares":3375},"source":{"system":"sec-edgar","filing":"0001127602-20-006015","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760220006015/form4.xml","form_type":"4"}},{"id":3266428,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Ordinary Shares","published_at":"2020-02-18T21:07:52.000Z","date":"2020-02-17","kind":"tax_withholding","acquired":false,"shares":904,"price":17.77,"value":16064.08,"ownership":{"direct":true},"balance_after":62555,"source":{"system":"sec-edgar","filing":"0001127602-20-006015","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760220006015/form4.xml","form_type":"4"}},{"id":3266427,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Ordinary Shares","published_at":"2020-02-18T21:07:52.000Z","date":"2020-02-17","kind":"exercise","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":63459,"source":{"system":"sec-edgar","filing":"0001127602-20-006015","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760220006015/form4.xml","form_type":"4"}},{"id":3266426,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Ordinary Shares","published_at":"2020-02-18T21:07:52.000Z","date":"2020-02-16","kind":"tax_withholding","acquired":false,"shares":1172,"price":17.77,"value":20826.44,"ownership":{"direct":true},"balance_after":60459,"source":{"system":"sec-edgar","filing":"0001127602-20-006015","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760220006015/form4.xml","form_type":"4"}},{"id":3266425,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Ordinary Shares","published_at":"2020-02-18T21:07:52.000Z","date":"2020-02-16","kind":"exercise","acquired":true,"shares":3375,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":61631,"source":{"system":"sec-edgar","filing":"0001127602-20-006015","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760220006015/form4.xml","form_type":"4"}},{"id":3291036,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2020-02-04T23:02:14.000Z","date":"2019-08-29","kind":"gift","acquired":false,"shares":1500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects the amount of securities beneficially owned by the reporting person as of December 31, 2019, which reflects a gift of 1,500 shares by the reporting person on August 29, 2019."}],"balance_after":1035,"source":{"system":"sec-edgar","filing":"0001562180-20-000855","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000156218020000855/primarydocument.xml","form_type":"5"}},{"id":3411976,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-09-17T23:06:40.000Z","date":"2019-09-13","kind":"exercise","acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options are fully vested in accordance with their terms."}],"balance_after":21983,"derivative":{"exercise_price":11.74,"expiration_date":"2020-05-17","underlying":"Ordinary Shares","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001127602-19-028600","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760219028600/form4.xml","form_type":"4"}},{"id":3411975,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Ordinary Shares","published_at":"2019-09-17T23:06:40.000Z","date":"2019-09-13","kind":"exercise","acquired":true,"shares":20000,"price":11.74,"value":234800.0,"ownership":{"direct":true},"balance_after":58256,"source":{"system":"sec-edgar","filing":"0001127602-19-028600","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760219028600/form4.xml","form_type":"4"}},{"id":3411974,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Ordinary Shares","published_at":"2019-09-17T23:06:40.000Z","date":"2017-12-15","kind":"gift","acquired":false,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes (a) 80,000 shares transferred to the Reporting Person on June 3, 2019 to satisfy an annuity payment from the Reporting Person's 2018 GRAT No. 1 (the James M. Frates Grantor Retained Annuity Trust dated February 22, 2018 and funded on February 23, 2018), and (b) 17,204 shares transferred to the Reporting Person on June 10, 2019 to satisfy an annuity payment from the Reporting Person's 2014 GRAT (the James M. Frates Grantor Retained Annuity Trust dated December 19, 2013 and funded on March 14, 2014), and (c) 43,331 shares transferred to the Reporting Person on June 11, 2019 to satisfy an annuity payment from the Reporting Person's 2018 GRAT No. 2 (the James M. Frates Grantor Retained Annuity Trust dated May 25, 2018 and funded on May 29, 2018), and excludes 150,000 shares previously owned directly, which were contributed on June 14, 2019 to the 2019 GRAT No. 1 (the James M. Frates 2019 Grantor Retained Annuity Trust No. 1 dated June 13, 2019), each of which transactions was exempt from the reporting obligations of Section 16 of the Securities Exchange Act of 1934, as amended (the \"Exchange Act\"), by virtue of Rule 16a-13 promulgated thereunder."}],"balance_after":38256,"source":{"system":"sec-edgar","filing":"0001127602-19-028600","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760219028600/form4.xml","form_type":"4"}},{"id":3435930,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-08-16T20:04:10.000Z","date":"2019-08-15","kind":"exercise","acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan and has vested in full on June 22, 2017."}],"balance_after":5922,"derivative":{"exercise_price":28.35,"expiration_date":"2026-06-22","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001562180-19-004305","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000156218019004305/primarydocument.xml","form_type":"4"}},{"id":3435929,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-16T20:04:10.000Z","date":"2019-08-15","kind":"sale","acquired":false,"shares":8000,"price":160.58,"value":1284640.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":2535,"source":{"system":"sec-edgar","filing":"0001562180-19-004305","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000156218019004305/primarydocument.xml","form_type":"4"}},{"id":3435928,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-16T20:04:10.000Z","date":"2019-08-15","kind":"exercise","acquired":true,"shares":8000,"price":28.35,"value":226800.0,"ownership":{"direct":true},"balance_after":10535,"source":{"system":"sec-edgar","filing":"0001562180-19-004305","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000156218019004305/primarydocument.xml","form_type":"4"}},{"id":3435927,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-16T20:04:10.000Z","date":"2019-05-06","kind":"gift","acquired":false,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2535,"source":{"system":"sec-edgar","filing":"0001562180-19-004305","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000156218019004305/primarydocument.xml","form_type":"4"}},{"id":3435926,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-08-16T20:04:10.000Z","date":"2019-05-06","kind":"gift","acquired":false,"shares":1200,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3035,"source":{"system":"sec-edgar","filing":"0001562180-19-004305","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000156218019004305/primarydocument.xml","form_type":"4"}},{"id":3498629,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-06-06T20:02:27.000Z","date":"2019-06-05","kind":"grant","acquired":true,"shares":10000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option award was issued pursuant to the Sage Therapeutics, Inc., 2014 Stock Option and Incentive Plan in accordance with the terms of the Amended and Restated Non-Employee Director Compensation Policy. The option will vest in full upon the earlier to occur of June 5, 2020 or the day immediately prior to the 2020 Annual Meeting of Sage's stockholders, subject to continued service as a director on such date."}],"balance_after":10000,"derivative":{"exercise_price":177.41,"expiration_date":"2029-06-05","underlying":"Common Stock","underlying_shares":10000},"source":{"system":"sec-edgar","filing":"0001562180-19-003391","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000156218019003391/primarydocument.xml","form_type":"4"}},{"id":3537872,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2019-05-06T22:21:37.000Z","date":"2019-05-06","kind":"exercise","acquired":false,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares subject to the option vested 33% on the first anniversary of the grant date and quarterly thereafter, such that 100% of the shares subject to the option were fully vested and exercisable on May 26, 2017."}],"balance_after":1309,"derivative":{"exercise_price":8.92,"expiration_date":"2024-05-21","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001562180-19-002643","document":"primarydocument.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000156218019002643/primarydocument.xml","form_type":"4"}},{"id":3537871,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-06T22:21:37.000Z","date":"2019-05-06","kind":"sale","acquired":false,"shares":8000,"price":162.22,"value":1297760.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported on this Form 4 were effected pursuant to a trading plan adopted pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended."}],"balance_after":4235,"source":{"system":"sec-edgar","filing":"0001562180-19-002643","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000156218019002643/primarydocument.xml","form_type":"4"}},{"id":3537870,"issuer":{"id":77038,"kind":"organization","name":"Sage Therapeutics, Inc.","symbol":"SAGE"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2019-05-06T22:21:37.000Z","date":"2019-05-06","kind":"exercise","acquired":true,"shares":8000,"price":8.92,"value":71360.0,"ownership":{"direct":true},"balance_after":12235,"source":{"system":"sec-edgar","filing":"0001562180-19-002643","document":"primarydocument.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000156218019002643/primarydocument.xml","form_type":"4"}},{"id":3618450,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Restricted Stock Unit Award","published_at":"2019-03-04T22:35:12.000Z","date":"2019-03-01","kind":"exercise","acquired":false,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/1/2017."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 3/1/2017."}],"balance_after":4500,"derivative":{"exercise_price":0,"exercise_date":"2017-03-01","underlying":"Ordinary Shares","underlying_shares":4500},"source":{"system":"sec-edgar","filing":"0001127602-19-009651","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760219009651/form4.xml","form_type":"4"}},{"id":3618449,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Ordinary Shares","published_at":"2019-03-04T22:35:12.000Z","date":"2019-03-01","kind":"tax_withholding","acquired":false,"shares":1323,"price":34.44,"value":45564.12,"ownership":{"direct":true},"balance_after":49721,"source":{"system":"sec-edgar","filing":"0001127602-19-009651","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760219009651/form4.xml","form_type":"4"}},{"id":3618448,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Ordinary Shares","published_at":"2019-03-04T22:35:12.000Z","date":"2019-03-01","kind":"exercise","acquired":true,"shares":4500,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":51044,"source":{"system":"sec-edgar","filing":"0001127602-19-009651","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760219009651/form4.xml","form_type":"4"}},{"id":3628707,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Restricted Stock Unit Award","published_at":"2019-02-27T22:12:59.000Z","date":"2019-02-26","kind":"exercise","acquired":false,"shares":2625,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"This RSU award is fully vested in accordance with its terms."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"This RSU award is fully vested in accordance with its terms."}],"balance_after":0,"derivative":{"exercise_price":0,"underlying":"Ordinary Shares","underlying_shares":2625},"source":{"system":"sec-edgar","filing":"0001127602-19-008739","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760219008739/form4.xml","form_type":"4"}},{"id":3628706,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Ordinary Shares","published_at":"2019-02-27T22:12:59.000Z","date":"2019-02-26","kind":"tax_withholding","acquired":false,"shares":772,"price":33.92,"value":26186.24,"ownership":{"direct":true},"balance_after":46544,"source":{"system":"sec-edgar","filing":"0001127602-19-008739","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760219008739/form4.xml","form_type":"4"}},{"id":3628705,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Ordinary Shares","published_at":"2019-02-27T22:12:59.000Z","date":"2019-02-26","kind":"exercise","acquired":true,"shares":2625,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":47316,"source":{"system":"sec-edgar","filing":"0001127602-19-008739","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760219008739/form4.xml","form_type":"4"}},{"id":3635511,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Restricted Stock Unit Award","published_at":"2019-02-25T22:13:03.000Z","date":"2019-02-21","kind":"grant","acquired":true,"shares":23300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/21/2020."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/21/2020."}],"balance_after":23300,"derivative":{"exercise_price":0,"exercise_date":"2020-02-21","underlying":"Ordinary Shares","underlying_shares":23300},"source":{"system":"sec-edgar","filing":"0001127602-19-008091","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760219008091/form4.xml","form_type":"4"}},{"id":3635510,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-02-25T22:13:03.000Z","date":"2019-02-21","kind":"grant","acquired":true,"shares":90600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares subject to the stock option award vest in four equal annual installments commencing on 2/21/2020."}],"balance_after":90600,"derivative":{"exercise_price":32.57,"exercise_date":"2020-02-21","expiration_date":"2029-02-21","underlying":"Ordinary Shares","underlying_shares":90600},"source":{"system":"sec-edgar","filing":"0001127602-19-008091","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760219008091/form4.xml","form_type":"4"}},{"id":3649320,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Restricted Stock Unit Award","published_at":"2019-02-19T23:53:42.000Z","date":"2019-02-17","kind":"exercise","acquired":false,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/17/18."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/17/18."}],"balance_after":6000,"derivative":{"exercise_price":0,"exercise_date":"2018-02-17","underlying":"Ordinary Shares","underlying_shares":3000},"source":{"system":"sec-edgar","filing":"0001127602-19-006969","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760219006969/form4.xml","form_type":"4"}},{"id":3649319,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Restricted Stock Unit Award","published_at":"2019-02-19T23:53:42.000Z","date":"2019-02-16","kind":"exercise","acquired":false,"shares":3375,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/16/19."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Shares subject to the restricted stock unit award vest in equal annual installments over a four year period, commencing on 2/16/19."}],"balance_after":10125,"derivative":{"exercise_price":0,"exercise_date":"2019-02-16","underlying":"Ordinary Shares","underlying_shares":3375},"source":{"system":"sec-edgar","filing":"0001127602-19-006969","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760219006969/form4.xml","form_type":"4"}},{"id":3649318,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Ordinary Shares","published_at":"2019-02-19T23:53:42.000Z","date":"2019-02-17","kind":"tax_withholding","acquired":false,"shares":875,"price":32.54,"value":28472.5,"ownership":{"direct":true},"balance_after":44691,"source":{"system":"sec-edgar","filing":"0001127602-19-006969","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760219006969/form4.xml","form_type":"4"}},{"id":3649317,"issuer":{"id":2392,"kind":"organization","name":"Alkermes plc.","symbol":"ALKS"},"owners":[{"id":21224,"kind":"person","name":"FRATES JAMES M","position":1,"cik":"0001235598","reported_name":"FRATES JAMES M","relationship":{"officer":true,"officer_title":"SVP, Alks Inc; CFO ALKS"}}],"security":"Ordinary Shares","published_at":"2019-02-19T23:53:42.000Z","date":"2019-02-17","kind":"exercise","acquired":true,"shares":3000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":45566,"source":{"system":"sec-edgar","filing":"0001127602-19-006969","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1235598/000112760219006969/form4.xml","form_type":"4"}}],"next_cursor":"2019-02-19T23:53:42.000000Z,3649317"}